|
|
||||||||


*
La Jolla Institute for Allergy and Immunology, San Diego, CA 92121; and
Cytel Corporation, San Diego, CA 92121
Treating mice with an immunodominant T cell epitope from moth cytochrome c (MCC88103) can induce T cell unresponsiveness under certain conditions of administration. In this report, we determined whether T cell tolerance to MCC88103 in adult animals can be overcome by immunization with cross-reactive analogues of the tolerizing Ag. A panel of analogues of the tolerogen were tested for their capacity to terminate the tolerant state following in vivo immunization. As analyzed by their stimulatory capacity for a representative MCC88103-specific T cell clone, this panel covered a wide range of cross-reactivity, including nonantigenic, antagonistic, weakly, and strongly antigenic peptides. Interestingly, only heteroclitic analogues, as measured in vitro by their enhanced antigenicity for the T cell clone that was specific for MCC88103, were capable of breaking tolerance. Thus, an immune response to the cross-reactive, heteroclitic analogues of tolerized self Ags may represent a mechanism by which Ag molecular mimicry operates.
This article has been cited by other articles:
![]() |
J. Lustgarten, A. L. Dominguez, and C. Pinilla Identification of Cross-Reactive Peptides Using Combinatorial Libraries Circumvents Tolerance against Her-2/neu-Immunodominant Epitope J. Immunol., February 1, 2006; 176(3): 1796 - 1805. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Illes, H. Waldner, J. Reddy, E. Bettelli, L. B. Nicholson, and V. K. Kuchroo T Cell Tolerance Induced by Cross-Reactive TCR Ligands Can Be Broken by Superagonist Resulting in Anti-Inflammatory T Cell Cytokine Production J. Immunol., August 1, 2005; 175(3): 1491 - 1497. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Lou, R. J. Kelleher Jr, A. Sette, J. Loyall, S. Southwood, R. B. Bankert, and S. H. Bernstein Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells Blood, August 1, 2004; 104(3): 752 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. J. Schreurs, K. B. J. Scholten, E. W. M. Kueter, J. J. Ruizendaal, C. J. L. M. Meijer, and E. Hooijberg In Vitro Generation and Life Span Extension of Human Papillomavirus Type 16-Specific, Healthy Donor-Derived CTL Clones J. Immunol., September 15, 2003; 171(6): 2912 - 2921. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kimachi, K. Sugie, and H. M. Grey Effector T cells have a lower ligand affinity threshold for activation than naive T cells Int. Immunol., July 1, 2003; 15(7): 885 - 892. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Yang and H. M. Grey Study of the Mechanism of TCR Antagonism Using Dual-TCR-Expressing T Cells J. Immunol., May 1, 2003; 170(9): 4532 - 4538. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Castilleja, D. Carter, C. L. Efferson, N. E. Ward, K. Kawano, B. Fisk, A. P. Kudelka, D. M. Gershenson, J. L. Murray, C. A. O'Brian, et al. Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex J. Immunol., October 1, 2002; 169(7): 3545 - 3554. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Buteau, S. N. Markovic, and E. Celis Challenges in the Development of Effective Peptide Vaccines for Cancer Mayo Clin. Proc., April 1, 2002; 77(4): 339 - 349. [Abstract] [PDF] |
||||
![]() |
D. A. Ostrov, M. M. Roden, W. Shi, E. Palmieri, G. J. Christianson, L. Mendoza, G. Villaflor, D. Tilley, N. Shastri, H. Grey, et al. How H13 Histocompatibility Peptides Differing by a Single Methyl Group and Lacking Conventional MHC Binding Anchor Motifs Determine Self-Nonself Discrimination J. Immunol., January 1, 2002; 168(1): 283 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. de Visser, T. A. Cordaro, H. W. H. G. Kessels, F. H. Tirion, T. N. M. Schumacher, and A. M. Kruisbeek Low-Avidity Self-Specific T Cells Display a Pronounced Expansion Defect That Can Be Overcome by Altered Peptide Ligands J. Immunol., October 1, 2001; 167(7): 3818 - 3828. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tangri, G. Y. Ishioka, X. Huang, J. Sidney, S. Southwood, J. Fikes, and A. Sette Structural Features of Peptide Analogs of Human Histocompatibility Leukocyte Antigen Class I Epitopes that Are More Potent and Immunogenic than Wild-Type Peptide J. Exp. Med., September 17, 2001; 194(6): 833 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fong, Y. Hou, A. Rivas, C. Benike, A. Yuen, G. A. Fisher, M. M. Davis, and E. G. Engleman Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy PNAS, June 20, 2001; (2001) 141226398. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Joshi, P. R. Suresh, and V. S. Chauhan Flexibility in MHC and TCR Recognition: Degenerate Specificity at the T Cell Level in the Recognition of Promiscuous Th Epitopes Exhibiting No Primary Sequence Homology J. Immunol., June 1, 2001; 166(11): 6693 - 6703. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Anderton, C. G. Radu, P. A. Lowrey, E. S. Ward, and D. C. Wraith Negative Selection during the Peripheral Immune Response to Antigen J. Exp. Med., December 27, 2000; 193(1): 1 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lu and E. Celis Use of Two Predictive Algorithms of the World Wide Web for the Identification of Tumor-reactive T-Cell Epitopes Cancer Res., September 1, 2000; 60(18): 5223 - 5227. [Abstract] [Full Text] |
||||
![]() |
L. Bouhdoud, P. Villain, A. Merzouki, M. Arella, and C. Couture T-Cell Receptor-Mediated Anergy of a Human Immunodeficiency Virus (HIV) gp120-Specific CD4+ Cytotoxic T-Cell Clone, Induced by a Natural HIV Type 1 Variant Peptide J. Virol., March 1, 2000; 74(5): 2121 - 2130. [Abstract] [Full Text] |
||||
![]() |
R. Wang, Y. Wang-Zhu, C. R. Gabaglia, K. Kimachi, and H. M. Grey The Stimulation of Low-Affinity, Nontolerized Clones by Heteroclitic Antigen Analogues Causes the Breaking of Tolerance Established to an Immunodominant T Cell Epitope J. Exp. Med., October 4, 1999; 190(7): 983 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fong, Y. Hou, A. Rivas, C. Benike, A. Yuen, G. A. Fisher, M. M. Davis, and E. G. Engleman Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy PNAS, July 17, 2001; 98(15): 8809 - 8814. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |